Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Portfolio Pulse from
Vaxcyte has initiated a Phase 2 study for VAX-31, a vaccine aimed at preventing invasive pneumococcal disease in infants. The company plans to release initial safety and efficacy data in mid-2026, with further data following nine months later.

December 03, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxcyte has started a Phase 2 trial for its VAX-31 vaccine, targeting invasive pneumococcal disease in infants. Initial data is expected in mid-2026, which could influence the company's stock based on the results.
The initiation of a Phase 2 trial is a significant step in the development of Vaxcyte's VAX-31 vaccine. Positive results could lead to further clinical trials and eventual market approval, potentially boosting the company's stock. The timeline for data release is set for mid-2026, which will be a critical point for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90